Cinnamic Acid

Cinnamic Acid

SCHEMBL3406486

O=C(O)/C=C\c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 1.00
HDAC3 O15379 2/20 1.00
HDAC4 P56524 2/20 1.00
HDAC1 Q13547 2/20 1.00
HDAC2 Q92769 2/20 1.00
HDAC8 Q9BY41 2/20 1.00
HDAC6 Q9UBN7 2/20 1.00
TNKS O95271 1/20 1.00
HDAC7 Q8WUI4 1/20 1.00
HDAC10 Q969S8 1/20 1.00
HDAC11 Q96DB2 1/20 1.00
TNKS2 Q9H2K2 1/20 1.00
HDAC9 Q9UKV0 1/20 1.00
HDAC5 Q9UQL6 1/20 1.00
PLIN1 O60240 2/20 0.73
LMNA P02545 2/20 0.73
MAPT P10636 2/20 0.73
RECQL P46063 2/20 0.73
PLIN5 Q00G26 2/20 0.73
ABHD5 Q8WTS1 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cinnamic Acid SCHEMBL1332 1.00 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL653828 1.00 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL50466 1.00 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL29989544 1.00 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL653827 1.00 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL1333 1.00 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL1706935 1.00 HCAR2 (1.00) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL579400 0.97 HCAR2 (0.95) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL6444122 0.97 HDAC3 (0.95) HCAR2HDAC3HDAC4HDAC1HDAC2
Cinnamic Acid SCHEMBL2816036 0.97 HCAR2 (0.95) HCAR2HDAC3HDAC4HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260051387-A1 METABOLOMIC ANALYSIS OF PERITONEAL DIALYSIS EFFLUENT FRESENIUS MEDICAL CARE HOLDINGS, INC. (US) 2026-02-19 US claimed
US-20240350441-A1 PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION Goldlake Lifesciences Pvt Ltd (IN) 2024-10-24 US claimed
CN-118813188-A Long-opening-time water-soluble formaldehyde-free adhesive and preparation method and application thereof 江苏艾科赛特新材料有限公司 2024-10-22 CN claimed
CN-118813173-A Formaldehyde-free adhesive with excellent water resistance and application thereof 江苏艾科赛特新材料有限公司 2024-10-22 CN claimed
EP-4440554-A1 A PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION Sava Healthcare Ltd (IN) 2024-10-09 EP claimed
CN-118541170-A Ionic liquid composition I2O治疗公司 2024-08-23 CN claimed
CN-118354764-A Pharmaceutical preparation and method for producing the same 萨瓦医疗保健有限公司 2024-07-16 CN claimed
CN-118027276-A Multipolymer, preparation method and application thereof, negative electrode slurry, negative electrode plate and lithium ion battery 北京卫蓝新能源科技有限公司 2024-05-14 CN claimed
US-20230390195-A1 STABLE COMPOSITIONS FOR INCRETIN MIMETIC COMPOUNDS DELPOR, INC. 2023-12-07 US claimed
WO-2023099968-A1 A PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION SAVA HEALTHCARE LTD (IN) 2023-06-08 WO claimed
WO-2016049404-A1 SUBSTRATES COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
WO-2016049398-A1 FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
WO-2016049407-A1 ABSORBENT ARTICLE COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
WO-2016049394-A1 CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
WO-2016049396-A1 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
WO-2016049455-A1 PERSONAL CARE COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
WO-2016049395-A1 PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS THE PROCTER & GAMBLE COMPANY (US) 2016-03-31 WO claimed
US-20160090556-A1 PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS THE PROCTER & GAMBLE COMPANY 2016-03-31 US claimed
US-20160090557-A1 SUBSTRATES COMPRISING MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2016-03-31 US claimed
US-20160089462-A1 FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME THE PROCTER & GAMBLE COMPANY 2016-03-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240350441-A1 PHARMACEUTICAL FORMULATION AND A PROCESS FOR ITS PREPARATION MYD88, NFATC1, CCR6 HCAR2 1563/4885HDAC3 3086/4885HDAC4 1152/4885
US-20260051387-A1 METABOLOMIC ANALYSIS OF PERITONEAL DIALYSIS EFFLUENT SLC43A1, SLC14A1, SLC1A5 HCAR2 60/4885HDAC3 3815/4885HDAC4 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.